Project Publications: University of Arizona: Data Management and Analysis Core

Superfund Research Program

Project Leader: Aikseng Ooi
Co-Investigator: Nirav Merchant
Grant Number: P42ES004940
Funding Period: 2020-2025

Anandhan A, Dodson M, Shakya A, Chen J, Liu P, Wei Y, Tan H, Wang Q, Jiang Z, Yang K, Garcia JG, Chambers SK, Chapman E, Ooi A, Yang-Hartwich Y, Stockwell BR, Zhang DD. 2023. NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8. Sci Adv 9(5):doi:10.1126/sciadv.ade9585 PMID:36724221 PMCID:PMC9891695

Dodson M, Dai W, Anandhan A, Schmidlin CJ, Liu P, Wilson NC, Wei Y, Kitamura N, Galligan JJ, Ooi A, Chapman E, Zhang DD. 2022. CHML is an NRF2 target gene that regulates mTOR function. Mol Oncol 16:1714-1727. doi:10.1002/1878-0261.13194 PMID:35184380 PMCID:PMC9019883
Kerimoglu B, Lamb C, McPherson RD, Ergen E, Stone EM, Ooi A. 2022. Cyst(e)inase-rapamycin combination induces ferroptosis in both in vitro and in vivo models of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 21(3):doi:10.1158/1535-7163.MCT-21-0661 PMID:35086957 PMCID:PMC8898288
Liu P, Anandhan A, Chen J, Shakya A, Dodson M, Ooi A, Chapman E, White E, Garcia JG, Zhang DD. 2022. Decreased autophagosome biogenesis, reduced NRF2, and enhanced ferroptotic cell death are underlying molecular mechanisms of non-alcoholic fatty liver disease. Redox Biol 59:102570. doi:10.1016/j.redox.2022.102570 PMID:36495698 PMCID:PMC9731892

Liu P, Dodson M, Li H, Schmidlin C, Shakya A, Wei Y, Garcia JG, Chapman E, Kiela PR, Zhang Q, White E, Ding X, Ooi A, Zhang DD. 2021. Non-canonical NRF2 activation promotes a pro-diabetic shift in hepatic glucose metabolism. Mol Metab 51:101243. doi:10.1016/j.molmet.2021.101243 PMID:33933676 PMCID:PMC8164084

Kerins M, Liu P, Tian W, Mannheim W, Zhang DD, Ooi A. 2019. Genome-wide CRISPR screen reveals autophagy disruption as the convergence mechanism that regulates the NRF2 transcription factor. Mol Cell Biol 39(13):e00037-19. doi:10.1128/MCB.00037-19 PMID:31010806 PMCID:PMC6580702